Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2015

View Archived Issues

Ablynx achieves preclinical PoC with Nanobody construct in Merck & Co. collaboration

Autotelic acquires rights to trabedersen from Isarna

RXi Pharmaceuticals reports interim data from phase IIa study of RXI-109

New company Decibel Therapeutics launched to address hearing loss

Novartis introduces JAK/TYK2 inhibitors

Actelion presents prostaglandin D2 receptor 2 antagonists

Rock Creek completes phase I trial of oral formulations of anatabine citrate

Novo Nordisk licenses use of Emisphere's Eligen technology for oral drug development

Sanofi Pasteur and IDRI create Global Health Vaccine Center of Innovation

Integral Molecular's Ebola antibody research supported by new NIAID award

Johnson & Johnson updates progress of third quarter 2015

Studies in vivo support clinical development of novel anti-miR-103/107 candidate RG-125

AbbVie's ABT-555 enters clinical evaluation for multiple sclerosis

Galapagos advances triple combination therapy in cystic fibrosis under AbbVie collaboration

FDA places partial clinical hold on beloranib

FDA approves Praxbind as dabigatran reversal agent

Genentech presents results from clinical trials of its anti-influenza antibody MHAA-4549A

Orion patents TRPA1 antagonists

Zheijiang University and Shanghai Institute of Materia Medica disclose PKB inhibitors

Merck KGaA and Cancer Research Technology divulge Wnt signaling inhibitors

Shionogi introduces anti-HIV agents

Lexicon describes orally active small-molecule inhibitors of NOTUM

New molecular probe [18F]5-FPN could be useful for melanoma diagnosis and staging

Phase I results for SUVN-G3031, a candidate to treat Alzheimer's disease

FDA requests additional data for lifitegrast NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...